Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

7th World Congress on Microbiology

Valencia, Spain

Patrick J Brennan

Patrick J Brennan

Colorado State University, USA

Title: The cell envelope of Mycobacterium tuberculosis and new drug discovery against tuberculosis

Biography

Biography: Patrick J Brennan

Abstract

Work of ours and others over the past 30 years has resulted in a thorough understanding of the structure of the mycobacterial cell wall and membranes but also the basic genetics and biosynthesis, providing essential targets for new drug development and molecular rationale for the bactericidal action of established antibiotics. The enzymology and underlying genetics of fatty acid and mycolic acids synthesis are well known and with it the mode of action of isoniazid, ethionamide, thiocarlides, thiolactomycin, etc. There is now convincing evidence that intercalated within this mycolic acids lipid environment are those ‘special’ (glycol) lipids; the phthiocerol dimycocerosates cord factor/dimycolyltrehalose, the sulfolipids, the phosphatidylinositol mannosides, etc., to form a true outer membrane (OM). Mycobacterial genetics and the creation of transposon and targeted mutant libraries has allowed definition of the synthesis of all of these entities, invaluable in comprehension of their roles in disease pathogenesis and aspects of the immune response; however, their general non-essentiality for bacterial growth limits their usefulness as targets for new drug development especially to counteract MDR-TB. The massive essential cell wall "core" of M. tuberculosis is comprised of peptidoglycan covalently attached via a linker unit (L‑Rha‑D‑GlcNAc‑P) to a linear galactofuran composed of Galf units, in turn attached to several strands of a highly branched arabinofuran (Araf), in turn attached to the mycolic acids. Definition of the genome of M. tuberculosis has greatly aided efforts to define the biosynthetic pathways leading to assembly of this cell wall core. Over the past 10 years we have painstakingly defined the essential enzymes in each of these pathways by knock-out and conditional mutagenesis and targeted the enzymes (e.g., all enzymes in the Rha synthetic pathway; the Galp mutase, the Galf and Araf transferases) by high and medium throughput screening of compound libraries. Yet, no promising leads have arisen from these efforts. Yet, the pursuit of interesting chemical entities by the research community, directly or via synthetic modifications has yielded some of the most promising lead compound now in our new drug armament. Examples are: the benzothiazinones, dinitrobenzamides and ethambutol inhibiting aspects of arabinan synthesis; CPZEN-45 inhibiting synthesis of the linker unit; the diarylquinolones and benzophenones addressing electron transport; thioureas inhibiting aspects of fatty acid synthesis; substituted triclosan derivatives and the nitroimidazoles inhibiting aspects of mycolic acids synthesis and several diamines involved in inhibition of the translocation of mycolic acids. These developments and others will be discussed in the context of current approaches to exploit our unprecedented knowledge of the biogenesis of the cell wall and membranes of M. tuberculosis for purposes of producing new and safe chemical scaffolds to address tuberculosis in its various aspects.